Alvaiz is a drug owned by Teva Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 05, 2038. Details of Alvaiz's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11072586 | Solid state forms of eltrombopag choline |
Nov, 2038
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Alvaiz's patents.
Latest Legal Activities on Alvaiz's Patents
Given below is the list of recent legal activities going on the following patents of Alvaiz.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Dec, 2024 | US11072586 |
| Patent Issue Date Used in PTA Calculation | 27 Jul, 2021 | US11072586 |
| Recordation of Patent Grant Mailed | 27 Jul, 2021 | US11072586 |
| Email Notification | 08 Jul, 2021 | US11072586 |
| Issue Notification Mailed | 07 Jul, 2021 | US11072586 |
| Application Is Considered Ready for Issue | 22 Jun, 2021 | US11072586 |
| Dispatch to FDC | 22 Jun, 2021 | US11072586 |
| Issue Fee Payment Received | 21 Jun, 2021 | US11072586 |
| Issue Fee Payment Verified | 21 Jun, 2021 | US11072586 |
| Email Notification | 03 May, 2021 | US11072586 |
US patents provide insights into the exclusivity only within the United States, but
Alvaiz is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Alvaiz's family patents as well as insights into
ongoing legal events
on those patents.
Alvaiz's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Alvaiz's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 05, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Alvaiz Generics:
There are no approved generic versions for Alvaiz as of now.
About Alvaiz
Alvaiz is a drug owned by Teva Pharmaceuticals Inc. Alvaiz uses Eltrombopag Choline as an active ingredient. Alvaiz was launched by Teva in 2023.
Approval Date:
Alvaiz was approved by FDA for market use on 29 November, 2023.
Active Ingredient:
Alvaiz uses Eltrombopag Choline as the active ingredient. Check out other Drugs and Companies using Eltrombopag Choline ingredient
Dosage:
Alvaiz is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 9MG BASE | TABLET | Prescription | ORAL |
| EQ 54MG BASE | TABLET | Prescription | ORAL |
| EQ 36MG BASE | TABLET | Prescription | ORAL |
| EQ 18MG BASE | TABLET | Prescription | ORAL |